ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration…
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir (AK0529) for the treatment of respiratory…